vs

Side-by-side financial comparison of MEDIFAST INC (MED) and TRUSTCO BANK CORP N Y (TRST). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $49.5M, roughly 1.5× TRUSTCO BANK CORP N Y). Over the past eight quarters, TRUSTCO BANK CORP N Y's revenue compounded faster (6.8% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

TRUSTCO BANK CORP N Y is a regional U.S. financial holding company that provides a full suite of retail and commercial banking products and services, including personal deposit accounts, mortgage loans, small business financing, and wealth management solutions. It primarily operates across New York, Florida, and several other U.S. states, serving individual consumers and small business client segments.

MED vs TRST — Head-to-Head

Bigger by revenue
MED
MED
1.5× larger
MED
$75.1M
$49.5M
TRST
Faster 2-yr revenue CAGR
TRST
TRST
Annualised
TRST
6.8%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MED
MED
TRST
TRST
Revenue
$75.1M
$49.5M
Net Profit
$16.3M
Gross Margin
69.4%
Operating Margin
-10.4%
Net Margin
32.9%
Revenue YoY
-36.9%
Net Profit YoY
14.1%
EPS (diluted)
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
TRST
TRST
Q1 26
$49.5M
Q4 25
$75.1M
$48.2M
Q3 25
$89.4M
$47.8M
Q2 25
$105.6M
$46.6M
Q1 25
$115.7M
$45.3M
Q4 24
$119.0M
$43.3M
Q3 24
$140.2M
$43.6M
Q2 24
$168.6M
$43.4M
Net Profit
MED
MED
TRST
TRST
Q1 26
$16.3M
Q4 25
$15.6M
Q3 25
$-2.3M
$16.3M
Q2 25
$2.5M
$15.0M
Q1 25
$-772.0K
$14.3M
Q4 24
$11.3M
Q3 24
$1.1M
$12.9M
Q2 24
$-8.2M
$12.6M
Gross Margin
MED
MED
TRST
TRST
Q1 26
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Operating Margin
MED
MED
TRST
TRST
Q1 26
Q4 25
-10.4%
43.7%
Q3 25
-4.6%
44.6%
Q2 25
-1.0%
42.3%
Q1 25
-1.1%
41.3%
Q4 24
0.6%
34.0%
Q3 24
1.5%
38.8%
Q2 24
-4.7%
37.9%
Net Margin
MED
MED
TRST
TRST
Q1 26
32.9%
Q4 25
32.3%
Q3 25
-2.5%
34.0%
Q2 25
2.3%
32.3%
Q1 25
-0.7%
31.5%
Q4 24
26.0%
Q3 24
0.8%
29.5%
Q2 24
-4.8%
28.9%
EPS (diluted)
MED
MED
TRST
TRST
Q1 26
Q4 25
$-1.64
$0.85
Q3 25
$-0.21
$0.86
Q2 25
$0.22
$0.79
Q1 25
$-0.07
$0.75
Q4 24
$0.08
$0.59
Q3 24
$0.10
$0.68
Q2 24
$-0.75
$0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
TRST
TRST
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
$112.9M
Stockholders' EquityBook value
$198.9M
$670.9M
Total Assets
$248.0M
$6.5B
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
TRST
TRST
Q1 26
Q4 25
$167.3M
$730.4M
Q3 25
$173.5M
$695.6M
Q2 25
$162.7M
$713.6M
Q1 25
$164.6M
$756.1M
Q4 24
$162.3M
$641.8M
Q3 24
$170.0M
$523.0M
Q2 24
$163.5M
$536.1M
Total Debt
MED
MED
TRST
TRST
Q1 26
$112.9M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
MED
MED
TRST
TRST
Q1 26
$670.9M
Q4 25
$198.9M
$686.6M
Q3 25
$214.7M
$692.0M
Q2 25
$216.0M
$692.8M
Q1 25
$211.0M
$687.8M
Q4 24
$210.1M
$676.3M
Q3 24
$207.3M
$669.0M
Q2 24
$205.3M
$655.2M
Total Assets
MED
MED
TRST
TRST
Q1 26
$6.5B
Q4 25
$248.0M
$6.4B
Q3 25
$268.2M
$6.3B
Q2 25
$269.3M
$6.3B
Q1 25
$280.0M
$6.3B
Q4 24
$284.2M
$6.2B
Q3 24
$291.2M
$6.1B
Q2 24
$293.5M
$6.1B
Debt / Equity
MED
MED
TRST
TRST
Q1 26
0.17×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
TRST
TRST
Operating Cash FlowLast quarter
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
TRST
TRST
Q1 26
Q4 25
$-5.3M
$57.6M
Q3 25
$12.1M
$12.8M
Q2 25
$-3.4M
$27.1M
Q1 25
$3.4M
$1.3M
Q4 24
$-4.9M
$59.4M
Q3 24
$9.1M
$16.5M
Q2 24
$13.1M
$18.7M
Free Cash Flow
MED
MED
TRST
TRST
Q1 26
Q4 25
$-6.6M
$45.7M
Q3 25
$10.8M
$10.0M
Q2 25
$-4.8M
$24.9M
Q1 25
$1.9M
$-3.3M
Q4 24
$-7.2M
$54.6M
Q3 24
$7.7M
$15.6M
Q2 24
$11.1M
$17.6M
FCF Margin
MED
MED
TRST
TRST
Q1 26
Q4 25
-8.8%
95.0%
Q3 25
12.0%
20.9%
Q2 25
-4.5%
53.5%
Q1 25
1.6%
-7.2%
Q4 24
-6.1%
126.0%
Q3 24
5.5%
35.7%
Q2 24
6.6%
40.5%
Capex Intensity
MED
MED
TRST
TRST
Q1 26
Q4 25
1.8%
24.6%
Q3 25
1.5%
5.9%
Q2 25
1.3%
4.5%
Q1 25
1.3%
10.0%
Q4 24
1.9%
11.3%
Q3 24
1.0%
2.1%
Q2 24
1.1%
2.6%
Cash Conversion
MED
MED
TRST
TRST
Q1 26
Q4 25
3.70×
Q3 25
0.79×
Q2 25
-1.36×
1.80×
Q1 25
0.09×
Q4 24
5.27×
Q3 24
8.04×
1.28×
Q2 24
1.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

TRST
TRST

Net Interest Income$44.7M90%
Noninterest Income$4.8M10%

Related Comparisons